A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With RO7790121 in Patients With Moderately to Severely Active Crohn's Disease
Latest Information Update: 06 Feb 2026
At a glance
- Drugs Afimkibart (Primary) ; Afimkibart (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Acronyms SIBERITE-1
- Sponsors Roche
Most Recent Events
- 07 Mar 2025 Planned initiation date changed from 28 Feb 2025 to 10 Mar 2025.
- 07 Mar 2025 Status changed from not yet recruiting to recruiting.
- 19 Feb 2025 New trial record